From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-exploratory-clinical-studies-provide-first-evidence-nyx Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced
From Startup Eidos Therapeutics Link to Full Article: http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-announces-positive-phase-2-data-ag10 AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28 AG10 Significantly Raised Serum TTR Concentrations (p90%
From Startup Neon Therapeutics Link to Full Article: – Management Hosting Webcast of Key Opinion Leader Discussion Today at 6:00 p.m. ET – CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today presents updated data from NT-001, its ongoing
From Startup iTeos Therapeutics Link to Full Article: http://www.iteostherapeutics.com/node/165 Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of two posters on its novel A2Areceptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 33rdAnnual
From Startup Aduro Biotech Link to Full Article: Data presented at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting demonstrate ADU-S100 (MIW815) is well-tolerated with no dose-limiting toxicities reported Preliminary signs of clinical and biomarker activity observed in patients with advanced cancers, including those pretreated with checkpoint inhibitor therapy Single
From Startup Urovant Link to Full Article: https://urovant.com/2018/11/05/urovant-sciences-to-report-2018-second-fiscal-quarter-financial-results/ BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Nov. 5, 2018– Urovant Sciences Ltd. (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced it will report 2018 second fiscal quarter financial results after the close of U.S. financial markets on Monday, November 12, 2018.
From Startup Urovant Link to Full Article: https://urovant.com/2018/11/08/urovant-sciences-completes-patient-enrollment-in-phase-3-pivotal-trial-studying-vibegron-for-overactive-bladder/ More than 1,500 patients enrolled in international Phase 3 clinical trial EMPOWUR, exceeding recruitment target Top-line efficacy and safety data from Phase 3 trial expected by the end of March 2019 BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Nov. 8, 2018– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company
From Startup Myovant Link to Full Article: http://investors.myovant.com/news-releases/2018/11-08-2018-210604964 BASEL, Switzerland, Nov. 8, 2018 /PRNewswire/ — Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women’s health and endocrine diseases, today announced corporate updates and reported financial results for the second fiscal quarter